Clinical trials: Myeloproliferative Neoplasm (MPN)
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and chronic myelomonocytic…
- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified
- Trial name
- NCT07468916
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04637009
- Testing
- TAS1553
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Clonal Mast Cell Disease, KIT D816V Mutation
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
- Conditions
- Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
- Trial name
- POLARIS (NCT07143669)
- Testing
- Screening
- Where
- 26 sites in United States, Belgium
- Volunteers
- 750 people
- Sponsor
- Blueprint Medicines Corporation
Polycythemia Vera, Essential Thrombocythemia
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis.
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- MPN-K (NCT03745378)
- Testing
- JAK2V617F mutation
- Where
- 30 sites in Czechia, Germany and 4 more
- Volunteers
- 1,881 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Anemia, Myelodysplastic/Myeloproliferative Neoplasm
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
This phase II trial studies the side effects of and how well sotatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis or anemia.
- Conditions
- Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
- Trial name
- NCT01712308
- Testing
- Sotatercept, Ruxolitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloproliferative Neoplasm
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms.
- Trial name
- NCT04103645
- Testing
- Vactosertib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Myeloproliferative Neoplasm (MPN), Polycytemia Vera
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN.
- Conditions
- Myeloproliferative Neoplasm (MPN), Polycytemia Vera, Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF)
- Trial name
- NCT07590986
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
Leukemia, Myelomonocytic, Chronic
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic…
- Trial name
- CMML/AML (NCT02807272)
- Testing
- Tipifarnib
- Where
- 8 sites in United States
- Volunteers
- 44 people
- Sponsor
- Kura Oncology, Inc.
Polycythemia Vera
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
This is an open-label, single-arm study of idasanutlin monotherapy in participants with hydroxyurea (HU)-resistant/intolerant Polycythemia vera (PV). The study will include two phases: initial phase and expansion phase.
- Trial name
- NCT03287245
- Testing
- Idasanutlin
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
The purpose of the study is to see if participants with anemia due to their type of MDS or MDS/MPN will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care, and what…
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Anemia
- Trial name
- NCT05732961
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies.
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome
- Trial name
- NCT05665530
- Testing
- PRT2527, Zanubrutinib, Venetoclax
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
- Trial name
- NCT04639024
- Testing
- ADCT-301
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gwynn Long, M.D.
Myeloproliferative Neoplasm
Evaluation of the Pathobiology of CALR-mutated MPN Cells
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
- Trial name
- NCT06480591
- Testing
- Blood Draw
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome)
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
The goal of this clinical trial is to evaluate the effectiveness and safety of the anti-NKG2A monoclonal antibody (Monalizumab) in patients undergoing haploidentical stem cell transplantation (Haplo-SCT) with post-transplantation…
- Conditions
- Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms)
- Trial name
- NCT06892223
- Testing
- Monalizumab (anti-NKG2A monoclonal antibody)
- Where
- 2 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Istituto Clinico Humanitas
Myeloproliferative Neoplasm
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients
The PERIBLOOD-MPN study aims to develop and validate a minimally invasive peripheral blood test using single-cell RNA sequencing to accurately diagnose and classify myeloproliferative neoplasms, potentially reducing the need for…
- Trial name
- NCT07648433
- Testing
- PERIBLOOD-MPN
- Volunteers
- 500 people
- Sponsor
- Weizmann Institute of Science
Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET)
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Myeloproliferative neoplasms (MPNs) are blood disorders that occur when the body makes too many white or red blood cells, or platelets.
- Conditions
- Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation, Polycythemia Vera (PV)
- Trial name
- AIRPORT-MPN (NCT04243122)
- Testing
- Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Ottawa Hospital Research Institute
Myeloproliferative Neoplasms
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
The purpose of this study is to test the safety and tolerability of ruxolitinib at different dose levels in combination with decitabine and the effectiveness of ruxolitinib in combination with decitabine in patients with…
- Trial name
- NCT02076191
- Testing
- Ruxolitinib, Decitabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- John Mascarenhas
Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF
Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation…
- Trial name
- NCT05115344
- Testing
- flonoltinib 25mg, flonoltinib 50mg, flonoltinib 100mg
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd